CA2087883A1 - Beta-alethine use in cell culture and therapy - Google Patents
Beta-alethine use in cell culture and therapyInfo
- Publication number
- CA2087883A1 CA2087883A1 CA 2087883 CA2087883A CA2087883A1 CA 2087883 A1 CA2087883 A1 CA 2087883A1 CA 2087883 CA2087883 CA 2087883 CA 2087883 A CA2087883 A CA 2087883A CA 2087883 A1 CA2087883 A1 CA 2087883A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- alethine
- beta
- mammal
- immunocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 title claims abstract 12
- 238000004113 cell culture Methods 0.000 title claims abstract 3
- 238000002659 cell therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 7
- 208000026278 immune system disease Diseases 0.000 claims abstract 6
- 238000000338 in vitro Methods 0.000 claims abstract 6
- 238000001727 in vivo Methods 0.000 claims abstract 5
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 230000036737 immune function Effects 0.000 claims 2
- 210000005170 neoplastic cell Anatomy 0.000 claims 2
- 230000009758 senescence Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000036448 vitalisation Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
.beta.-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of .beta.-alethine in the treatment of immune disorders and diseases, especially neoplasia, and in the promotion of cell cultures.
.beta.-alethine is employed in the differentiation, phenotypic expression, and vitalization of cells, for both in vivo and in vitro applications. Particular applications include the use of .beta.-alethine in the treatment of immune disorders and diseases, especially neoplasia, and in the promotion of cell cultures.
Claims (15)
1. A method for regulating cell function or bioproduction comprising exposing the cell, in vitro or in vivo, to an amount of .beta.-alethine, or physiologically compatible salt thereof, sufficient to normalize or improve function or bioproduction of the cell.
2. The method of Claim 1, wherein the cell is mammalian, including a human cell.
3. The method of Claim 2, wherein the cell is infected with a pathogen, including a virus.
4. The method of Claim 2, wherein the cell is an immunocyte or a neoplastic cell.
5. The method of Claim 1, wherein the cell is an immunocyte exposed to sufficient .beta.-alethine to normalize or improve immunological surveillance.
6. The method of Claim 1, wherein the cell is exposed, in vitro, to from at least about 10 pg .beta.-alethine/ml cell culture, or, in vivo, from at least about 10 pg .beta.-alethine/kg weight of the organism.
7. A method for treating neoplasia in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount suffi-cient to reduce tumor burden, induce regression of the tumor, or inhibit tumor growth or metastasis, optionally in conjunction with debulking of a tumor.
8. The method of Claim 7, wherein the neoplasia is hematolymphoid.
9. A method for treating immune disease or disorder in a mammal, including a human, comprising administering to the mammal .beta.-alethine, or a physiologically compatible salt thereof, in an amount sufficient to improve or normalize immunological function or bioproduction in the mammal.
10. The method of Claim 9, wherein the immune disease or disorder is an autoimmune disease or disorder, or an immunodefi-ciency disease or disorder, including AIDS or hypogammaglobuli-nemia.
11. The method of Claim 1 for improving or normalizing immunocyte function or bioproduction in a mammal, including a human, comprising extracting an immunocyte from the mammal, exposing the immunocyte, in vitro, or sufficient .beta.-alethine to stimulate immune function or bioproduction thereof, and thereaf-ter reintroducing the stimulated immunocyte into the afflicted mammal.
12. The method of Claim 11, wherein the mammal is afflicted with neoplasia, and the immunocyte is additionally stimulated by exposure to the neoplastic cell prior to the reintroduction of the immunocyte into the mammal.
13. A method for delaying the onset of senescence comprising exposing a presenescent cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to delay senescence thereof.
14. A method for adapting a culture-resistant cell of an organism to culture, comprising exposing the resistant cell, in vivo or in vitro, to .beta.-alethine in an amount sufficient to adapt the cell to culture.
15. The method of Claim 1, wherein a cell of an organism is additionally exposed to at least one factor which promotes either the maintenance or growth of the cell, or both.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002481077A CA2481077A1 (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91925392A | 1992-07-27 | 1992-07-27 | |
| US07/919,253 | 1992-07-27 | ||
| US92497792A | 1992-08-05 | 1992-08-05 | |
| US07/924,977 | 1992-08-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002481077A Division CA2481077A1 (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2087883A1 true CA2087883A1 (en) | 1994-01-28 |
| CA2087883C CA2087883C (en) | 2010-09-14 |
Family
ID=27129768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2087883 Expired - Lifetime CA2087883C (en) | 1992-07-27 | 1993-01-22 | Beta-alethine use in cell culture and therapy |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2087883C (en) |
-
1993
- 1993-01-22 CA CA 2087883 patent/CA2087883C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2087883C (en) | 2010-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kleinerman et al. | Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II) | |
| PT1059929E (en) | Isolated stromal cells for use in the treatment of diseases of the central nervous system | |
| Ashworth et al. | Some effects of BZ-55 (carbutamide) on the growth of the islets of Langerhans | |
| Ballas | Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. | |
| Dwarakanath et al. | Modification of the radiation induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas | |
| Argall et al. | Interactions between CD4+ T-cells and rat Schwann cells in vitro: 1. Antigen presentation by Lewis rat Schwann cells to P2-specific CD4+ T-cell lines | |
| CA2087883A1 (en) | Beta-alethine use in cell culture and therapy | |
| Balasch et al. | Intravenous immunoglobulin preceding in vitro fertilization-embryo transfer for patients with repeated failure of embryo transfer | |
| DE69113802T2 (en) | APPLICATION OF BETA ALETHINE IN CELL CULTURE AND THERAPY. | |
| HU189706B (en) | Improved process for the production of interferon | |
| Schmähl et al. | Experimental investigations on the influence upon the chemical carcinogenesis: 1st communication: Studies with ethylnitroso-urea | |
| Levo et al. | Hydantoin immunosuppression and carcinogenesis | |
| Holmes et al. | The radiation dose-rate effect in two human neuroblastoma cell lines | |
| Cory et al. | Calcium ion-dependent proliferation of L1210 cells in culture | |
| Cercek et al. | Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix | |
| Giacovazzo et al. | Relationship between HLA system in cluster headache and clinical response to lithium therapy | |
| Zhong et al. | Control and surveillance of filariasis in Shandong | |
| JPS6461420A (en) | Alpha-ethiocholanedione drug, and method of causing high hematic concentration alpha-ethiocholanone | |
| Naumov et al. | Autonomous device for photostimulation of the gastrointestinal tract immunity | |
| Pashchenko et al. | Effect of alcoholic patients' serum on the reproductive activity of human embryo fibroblasts | |
| Levo et al. | Increased incidence of urethane induced lung adenomata by autosensitized lymphocytes | |
| Wierowski et al. | Critical periods during the in situ repair of radiation-induced DNA damage in rat cerebellar neurons and 9L brain tumor cells | |
| Al-Joofy et al. | Effect of Continuous Darkness on Immune Response (In vivo Assay) | |
| Shaklee et al. | Endocrine and behavioral effects of intensive schedules of electroconvulsive shock | |
| Schmähl et al. | Experimental investigations on the influence upon the chemical carcinogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDC | Correction of dead application (reinstatement) | ||
| MKEX | Expiry |
Effective date: 20130122 |